Cancer Growth Inhibitors Market & Clinical Pipeline Analysis
|出版日期||內容資訊||英文 1000 Pages
|癌症增生抑制劑的市場及臨床實驗平台分析 Cancer Growth Inhibitors Market & Clinical Pipeline Analysis|
|出版日期: 2015年04月01日||內容資訊: 英文 1000 Pages||
全球製藥產業到目前為止，經過多年的研究和大金額的投資終於開發出了許多癌症治療藥。現在，每年也有許多的癌症治療藥重新上市。大型製藥企業投資大金額在研究開發 (R&D) 活動上進行臨床實驗平台的擴充，癌症抑制劑的市場競爭今後應將更為活躍。
本報告提供全球的癌症增生抑制劑臨床實驗進展相關分析、技術上的特性和主要的推動及阻礙市場要素、主要藥物 (癌症蛋白酪氨酸激酶、HDAC抑制劑、MTOR蛋白質抑制劑、PI3k抑制劑、蛋白酶體抑制劑) 的目前臨床實驗進展、主要企業簡介等資訊彙整，為您概述為以下內容。
Pharmaceutical industry consists of various products for cancer treatment and several years of research along with significant investments have helped in developing many innovative products. Every year, new cancer therapeutic belonging to different drug category is introduced across the globe. Cancer growth inhibitors are recent additions as compared to conventional therapeutics which have modest pharmacological potential. Pharmaceutical companies have been able to introduce newer cancer growth inhibitors for different cancer categories to overcome therapeutic and commercialization barriers. Due to higher investments in research and development, their clinical pipeline is becoming stronger and novel cancer growth inhibitors for different cancers are entering in global market. Their rate of market introduction is expected to increase in coming years due to technological advancements and increased funding. Consequently, market introduction of these cancer growth inhibitors is expected to offer severe competition to existing cancer therapeutics in global market.
Cancer growth inhibitors market shows overlapping boundaries due to which it becomes difficult to demarcate different categories. For instance, a tyrosine kinase may be a small molecules or a large molecule because they have same inhibitory molecule. On the other hand, they may inhibit cellular processes and belong to different molecular classes. Despite these differences, cancer growth inhibitors occupy large market shares and targeted therapeutics seems to be the major contenders. They have high safety and efficacy profiles along with minimized side effects due to which large number of patients are including them as a part of their regular therapeutic regime. In coming years, they are expected to become main focus of pharmaceutical companies because conventional cancer therapies like chemotherapy have proved to have modest efficacy. In future, their therapeutic efficacy is expected to increase and many innovative products are at different phases of clinical development due to which their global market is expected to witness steady growth.
Clinical pipeline of cancer growth inhibitors is increasing due to innovations and potential competition from newly developed cancer drugs. Pharmaceutical companies are focusing on approaches like utilization of next generation sequencing and computerized simulation to prevent undue wastage of time and resources. Relapse is another biggest issues associated with conventional cancer therapeutics which could be prevented with the help of cancer growth inhibitors. Innovative cancer growth inhibitors are expected to increase average survival time and decrease mortality rates. These factors are expected to increase the demand for cancer growth inhibitors but still lots of modalities have to be streamlined in order to offer sustainable competition to newly coming cancer therapeutics belonging to other drug categories. One of the major steps in order to overcome these shortcomings could be the utilization of high end technology.